I''d imagine one of the most tedious and tiring of jobs on the desk of any CEO of a listed entity is convincing the investment public of his or her views of the company and its prospects. When it's done well and everyone, and more importantly, analysts, are on the same page, it's a smooth ride and what normally follows is a rapidly rising share price as the company basks in the hope of future profits. The opposite is also true, when a CEO loses his investment community and the questions get just that bit more difficult to answer. Or the answers become just a bit too "high grade" for analysts to understand. In such cases, the share reacts, sometimes violently. Stephen Saad, the founding CEO of Aspen Pharmacare, has experienced both sides of the story. He was a beneficiary of market affection that knew no bounds about five years ago, when he was lauded by London's Financial Times and named on Forbes magazine's list of African billionaires as he rode the crest of a wave of stock that w...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, Morningstar financial data, and digital access to the Sunday Times and Times Select.

Already subscribed? Simply sign in below.

Questions or problems? Email helpdesk@businesslive.co.za or call 0860 52 52 00.